NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lumen Bioscience

Lumen Bioscience

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.lumen.bio/

Last Round

Series C

Extension

Oct 8, 2025

Total Funding Raised

$126.95M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Lumen Bioscience is a biotechnology company that develops oral biologic drugs and vaccine candidates using a proprietary spirulina-based platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biologic drugsspirulina platformbiomanufacturingorally delivered biologicsbio-pharmamedical countermeasuresinfectious diseasebiologic productiondrug developmentclinical-stage biotechbiotech startupsynthetic biologybioprocess optimizationantibody alternatives

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lumen Bioscience Comps

Public and private peers based on sector, stage, and business model.

Lumen Bioscience comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Lumen Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionOct 8, 2025
GrantOct 17, 2023
Series CJun 1, 2022
GrantJan 27, 2021
Series BSep 1, 2020
Grant
Dec 5, 2017

Key People

Founding team and executive leadership

Brian Finrow

CEO Founder

Founding Team

Lumen Bioscience Investors

Notable investors and investment history

Lumen Bioscience investors
InvestorRounds
CARB-XGrant
U.S. Department of DefenseGrant
Gates Family FoundationSeries C Extension
Gates FoundationGrant, Series C Extension
Public Health Emergency Medical Countermeasures EnterpriseGrant
WestRiver GroupSeries C Extension, Series B
U.S. Department of WarGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 10, 2026

    Achieved FSCC 22000 food safety certification.

  • Oct 8, 2025

    Jeff Raikes, former Microsoft president, joins the board.

Lumen Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lumen Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lumen Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range112
Year Founded2017
Last FundingOct 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.